The action comes days after Pfizer Inc. and its German partner BioNTech announced that its vaccine appears 95% effective at preventing mild to severe COVID-19 disease in a large, ongoing study. The action comes days after Pfizer Inc. and its German partner BioNTech announced that its vaccine appears 95% effective at preventing mild to severe COVID-19 disease in a large, ongoing study. Not far behind is competitor Moderna Inc.’s COVID-19 vaccine. “We don’t know what that vote’s going to be,” said former FDA vaccine chief Norman Baylor. A decision on Pfizer’s vaccine won’t affect other COVID-19 vaccine candidates in the pipeline, which will be judged separately.

Source: The Hindu November 20, 2020 12:32 UTC